Fenretinide is a synthetic retinoid primarily investigated for its potential in cancer prevention and treatment. It has shown promise in clinical trials for reducing the risk of breast cancer and prostate cancer recurrence by inducing apoptosis in cancer cells and inhibiting tumor growth. Additionally, it is being studied for treating neuroblastoma, a childhood cancer, due to its selective targeting of cancer cells. Beyond oncology, Fenretinide is explored for therapeutic effects in metabolic disorders, such as regulating lipid metabolism in obesity and diabetes, and in ocular diseases like dry eye syndrome, where it protects against degenerative conditions. Its unique mechanism involving retinoic acid receptor modulation makes it a versatile compound in medical research. Note: Usage remains experimental, requiring further studies for efficacy and safety.